Genscript Biotech Stock Price Prediction

GNNSF Stock  USD 1.37  0.01  0.72%   
As of 27th of November 2024, the relative strength index (RSI) of Genscript Biotech's share price is approaching 36. This usually indicates that the pink sheet is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Genscript Biotech, making its price go up or down.

Oversold Vs Overbought

36

 
Oversold
 
Overbought
The successful prediction of Genscript Biotech's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Genscript Biotech and does not consider all of the tangible or intangible factors available from Genscript Biotech's fundamental data. We analyze noise-free headlines and recent hype associated with Genscript Biotech, which may create opportunities for some arbitrage if properly timed.
Using Genscript Biotech hype-based prediction, you can estimate the value of Genscript Biotech from the perspective of Genscript Biotech response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Genscript Biotech to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Genscript because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Genscript Biotech after-hype prediction price

    
  USD 1.37  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Genscript Biotech Basic Forecasting Models to cross-verify your projections.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Genscript Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.061.193.21
Details

Genscript Biotech After-Hype Price Prediction Density Analysis

As far as predicting the price of Genscript Biotech at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Genscript Biotech or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Genscript Biotech, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Genscript Biotech Estimiated After-Hype Price Volatility

In the context of predicting Genscript Biotech's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Genscript Biotech's historical news coverage. Genscript Biotech's after-hype downside and upside margins for the prediction period are 0.07 and 3.39, respectively. We have considered Genscript Biotech's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
1.37
1.37
After-hype Price
3.39
Upside
Genscript Biotech is very risky at this time. Analysis and calculation of next after-hype price of Genscript Biotech is based on 3 months time horizon.

Genscript Biotech Pink Sheet Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Genscript Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genscript Biotech backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Genscript Biotech, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.14 
2.03
 0.00  
  0.01 
0 Events / Month
12 Events / Month
In a few days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
1.37
1.37
0.00 
0.00  
Notes

Genscript Biotech Hype Timeline

Genscript Biotech is currently traded for 1.37. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. Genscript is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is currently at -0.14%. %. The volatility of related hype on Genscript Biotech is about 5328.75%, with the expected price after the next announcement by competition of 1.36. About 38.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 200.0. Genscript Biotech recorded a loss per share of 0.17. The entity last dividend was issued on the 5th of June 2017. Assuming the 90 days horizon the next projected press release will be in a few days.
Check out Genscript Biotech Basic Forecasting Models to cross-verify your projections.

Genscript Biotech Related Hype Analysis

Having access to credible news sources related to Genscript Biotech's direct competition is more important than ever and may enhance your ability to predict Genscript Biotech's future price movements. Getting to know how Genscript Biotech's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Genscript Biotech may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
TLPPFTelix Pharmaceuticals Limited 0.00 0 per month 3.71  0.01  5.78 (5.49) 18.38 
KROSKeros Therapeutics(0.79)9 per month 2.13  0.09  4.39 (4.31) 16.94 
ZNTLZentalis Pharmaceuticals Llc 0.05 9 per month 5.20  0.03  11.41 (8.64) 33.76 
IVBXFInnovent Biologics 0.00 0 per month 0.00 (0.06) 5.48 (7.81) 24.34 
CLRPFClarity Pharmaceuticals 0.00 0 per month 0.00 (0.04) 10.48 (8.55) 22.62 
ONTTFOxford Nanopore Technologies 0.00 0 per month 4.04  0.02  11.11 (7.58) 21.94 
NUVLNuvalent 0.63 10 per month 2.69  0.03  3.84 (4.61) 36.85 
CRNXCrinetics Pharmaceuticals 1.32 9 per month 2.43 (0.01) 3.67 (3.45) 16.75 
INBXInhibrx 1.00 6 per month 2.70  0.03  5.54 (6.11) 16.80 
MRUSMerus BV(1.93)8 per month 0.00 (0.17) 3.08 (2.83) 10.85 
LYELLyell Immunopharma(0.07)6 per month 0.00 (0.10) 13.39 (9.47) 36.92 
KRONKronos Bio 0.01 9 per month 0.00 (0.07) 5.56 (6.25) 16.20 
AGEAgeX Therapeutics 0.00 0 per month 4.99  0.06  8.20 (9.20) 47.55 
LCTXLineage Cell Therapeutics(0.04)5 per month 0.00 (0.13) 7.14 (5.49) 39.60 
CVKDCadrenal Therapeutics, Common(0.95)10 per month 6.26  0.14  17.85 (9.54) 47.47 
ICCCImmuCell(0.08)5 per month 2.33 (0.03) 3.40 (3.29) 21.64 
NLTXNeoleukin Therapeutics(0.14)1 per month 0.00 (0.08) 4.05 (3.53) 27.84 
NUVBNuvation Bio 0.21 8 per month 4.59 (0) 9.48 (8.36) 21.30 
OVIDOvid Therapeutics 0.02 7 per month 0.00 (0.05) 5.93 (6.25) 19.20 
NXTCNextCure(0.06)5 per month 0.00 (0.14) 5.22 (6.37) 21.68 
CNTBConnect Biopharma Holdings 0.02 5 per month 5.33  0.01  12.12 (9.01) 48.67 

Genscript Biotech Additional Predictive Modules

Most predictive techniques to examine Genscript price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Genscript using various technical indicators. When you analyze Genscript charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Genscript Biotech Predictive Indicators

The successful prediction of Genscript Biotech stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Genscript Biotech, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Genscript Biotech based on analysis of Genscript Biotech hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Genscript Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Genscript Biotech's related companies.

Story Coverage note for Genscript Biotech

The number of cover stories for Genscript Biotech depends on current market conditions and Genscript Biotech's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Genscript Biotech is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Genscript Biotech's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Other Macroaxis Stories

Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios

Genscript Biotech Short Properties

Genscript Biotech's future price predictability will typically decrease when Genscript Biotech's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Genscript Biotech often depends not only on the future outlook of the potential Genscript Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Genscript Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding2.1 B

Complementary Tools for Genscript Pink Sheet analysis

When running Genscript Biotech's price analysis, check to measure Genscript Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genscript Biotech is operating at the current time. Most of Genscript Biotech's value examination focuses on studying past and present price action to predict the probability of Genscript Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genscript Biotech's price. Additionally, you may evaluate how the addition of Genscript Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data